1. Home
  2. REPL vs XNET Comparison

REPL vs XNET Comparison

Compare REPL & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • XNET
  • Stock Information
  • Founded
  • REPL 2015
  • XNET 2003
  • Country
  • REPL United States
  • XNET China
  • Employees
  • REPL N/A
  • XNET N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • XNET Computer Software: Prepackaged Software
  • Sector
  • REPL Health Care
  • XNET Technology
  • Exchange
  • REPL Nasdaq
  • XNET Nasdaq
  • Market Cap
  • REPL 547.0M
  • XNET 457.9M
  • IPO Year
  • REPL 2018
  • XNET 2014
  • Fundamental
  • Price
  • REPL $5.80
  • XNET $7.50
  • Analyst Decision
  • REPL Hold
  • XNET
  • Analyst Count
  • REPL 9
  • XNET 0
  • Target Price
  • REPL $7.00
  • XNET N/A
  • AVG Volume (30 Days)
  • REPL 2.5M
  • XNET 1.9M
  • Earning Date
  • REPL 11-11-2025
  • XNET 08-14-2025
  • Dividend Yield
  • REPL N/A
  • XNET N/A
  • EPS Growth
  • REPL N/A
  • XNET 5056.12
  • EPS
  • REPL N/A
  • XNET 11.50
  • Revenue
  • REPL N/A
  • XNET $355,826,000.00
  • Revenue This Year
  • REPL N/A
  • XNET N/A
  • Revenue Next Year
  • REPL $408.25
  • XNET N/A
  • P/E Ratio
  • REPL N/A
  • XNET $0.63
  • Revenue Growth
  • REPL N/A
  • XNET 11.15
  • 52 Week Low
  • REPL $2.68
  • XNET $1.51
  • 52 Week High
  • REPL $17.00
  • XNET $8.80
  • Technical
  • Relative Strength Index (RSI)
  • REPL 47.90
  • XNET 60.77
  • Support Level
  • REPL $5.74
  • XNET $7.05
  • Resistance Level
  • REPL $6.15
  • XNET $7.68
  • Average True Range (ATR)
  • REPL 0.35
  • XNET 0.44
  • MACD
  • REPL 0.12
  • XNET -0.06
  • Stochastic Oscillator
  • REPL 41.03
  • XNET 74.73

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

Share on Social Networks: